PMID- 27322496
OWN - NLM
STAT- MEDLINE
DCOM- 20171002
LR  - 20181113
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 12
IP  - 10
DP  - 2016 Oct 2
TI  - Dendritic cell vaccination in melanoma patients: From promising results to future 
      perspectives.
PG  - 2523-2528
LID - 10.1080/21645515.2016.1197453 [doi]
AB  - Dendritic cells (DCs) play an important role in the induction of antitumor 
      immunity. Therefore, they are used as anti-cancer vaccines in clinical studies in 
      various types of cancer. DC vaccines are generally well tolerated and able to 
      induce antigen-specific T cell responses in melanoma patients. After DC 
      vaccinations, functional tumor-specific T cells are more frequently detected in 
      stage III melanoma patients, as compared to patients with advanced melanoma, 
      indicating that the tumor load influences immunological responses. Furthermore, 
      long-lasting clinical responses were rarely seen in metastatic melanoma patients 
      after DC vaccination. Since more potent treatment options are available, e.g. 
      immune checkpoint inhibitors and targeted therapy, DC vaccination as monotherapy 
      may not be preferred in the treatment of advanced melanoma. However, encouraging 
      results of DC vaccines combined with ipilimumab have been reported in advanced 
      melanoma patients with an objective response rate of 38%. DC vaccines show 
      promising clinical results in stage III patients, although clinical efficacy 
      still needs to be proven in a phase 3 trial. The clinical and immunological 
      results of DC vaccination in stage III melanoma patients might be further 
      improved by using naturally circulating DCs (myeloid DCs and plasmacytoid DCs) 
      and neoantigens to load DCs.
FAU - Boudewijns, Steve
AU  - Boudewijns S
AD  - a Department of Medical Oncology , Radboud University Medical Center , Nijmegen , 
      The Netherlands.
AD  - b Department of Tumor Immunology , Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences , Nijmegen , The Netherlands.
FAU - Bloemendal, Martine
AU  - Bloemendal M
AD  - a Department of Medical Oncology , Radboud University Medical Center , Nijmegen , 
      The Netherlands.
AD  - b Department of Tumor Immunology , Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences , Nijmegen , The Netherlands.
FAU - Gerritsen, Winald R
AU  - Gerritsen WR
AD  - a Department of Medical Oncology , Radboud University Medical Center , Nijmegen , 
      The Netherlands.
FAU - de Vries, I Jolanda M
AU  - de Vries IJ
AD  - b Department of Tumor Immunology , Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences , Nijmegen , The Netherlands.
FAU - Schreibelt, Gerty
AU  - Schreibelt G
AD  - b Department of Tumor Immunology , Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences , Nijmegen , The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20160620
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Antibodies, Monoclonal/administration & dosage
MH  - Cancer Vaccines/*administration & dosage
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Ipilimumab
MH  - Melanoma/*therapy
MH  - T-Lymphocytes/*immunology
PMC - PMC5084999
OTO - NOTNLM
OT  - Dendritic cell vaccination
OT  - immune checkpoint inhibitors
OT  - immune response
OT  - melanoma
OT  - naturally circulating dendritic cells
OT  - neoantigens
EDAT- 2016/06/21 06:00
MHDA- 2017/10/03 06:00
PMCR- 2017/06/20
CRDT- 2016/06/21 06:00
PHST- 2016/06/21 06:00 [pubmed]
PHST- 2017/10/03 06:00 [medline]
PHST- 2016/06/21 06:00 [entrez]
PHST- 2017/06/20 00:00 [pmc-release]
AID - 1197453 [pii]
AID - 10.1080/21645515.2016.1197453 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2016 Oct 2;12(10):2523-2528. doi: 
      10.1080/21645515.2016.1197453. Epub 2016 Jun 20.